These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31489613)

  • 1. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01.
    Van Maele L; Fougeron D; Cayet D; Chalon A; Piccioli D; Collignon C; Sirard JC; Didierlaurent AM
    Eur J Immunol; 2019 Dec; 49(12):2134-2145. PubMed ID: 31489613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01.
    Bosteels C; Fierens K; De Prijck S; Van Moorleghem J; Vanheerswynghels M; De Wolf C; Chalon A; Collignon C; Hammad H; Didierlaurent AM; Lambrecht BN
    Front Immunol; 2020; 11():606805. PubMed ID: 33519816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
    Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
    J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant system AS01: helping to overcome the challenges of modern vaccines.
    Didierlaurent AM; Laupèze B; Di Pasquale A; Hergli N; Collignon C; Garçon N
    Expert Rev Vaccines; 2017 Jan; 16(1):55-63. PubMed ID: 27448771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant system AS01: from mode of action to effective vaccines.
    Roman F; Burny W; Ceregido MA; Laupèze B; Temmerman ST; Warter L; Coccia M
    Expert Rev Vaccines; 2024; 23(1):715-729. PubMed ID: 39042099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
    Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
    J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
    Garçon N; Van Mechelen M
    Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
    Coccia M; Collignon C; Hervé C; Chalon A; Welsby I; Detienne S; van Helden MJ; Dutta S; Genito CJ; Waters NC; Deun KV; Smilde AK; Berg RAVD; Franco D; Bourguignon P; Morel S; Garçon N; Lambrecht BN; Goriely S; Most RV; Didierlaurent AM
    NPJ Vaccines; 2017; 2():25. PubMed ID: 29263880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional and epigenetic changes in monocytes from adults immunized with an AS01-adjuvanted vaccine.
    Bechtold V; Smolen KK; Burny W; de Angelis SP; Delandre S; Essaghir A; Marchant A; Ndour C; Taton M; van der Most R; Willems F; Didierlaurent AM
    Sci Transl Med; 2024 Jul; 16(758):eadl3381. PubMed ID: 39083587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-Action.
    Buckley PR; Alden K; Coccia M; Chalon A; Collignon C; Temmerman ST; Didierlaurent AM; van der Most R; Timmis J; Andersen CA; Coles MC
    Front Immunol; 2019; 10():2150. PubMed ID: 31572370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.
    Lacaille-Dubois MA
    Phytomedicine; 2019 Jul; 60():152905. PubMed ID: 31182297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPL Adjuvant Contains Competitive Antagonists of Human TLR4.
    Wang YQ; Bazin-Lee H; Evans JT; Casella CR; Mitchell TC
    Front Immunol; 2020; 11():577823. PubMed ID: 33178204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.
    Desbien AL; Dubois Cauwelaert N; Reed SJ; Bailor HR; Liang H; Carter D; Duthie MS; Fox CB; Reed SG; Orr MT
    J Immunol; 2016 Dec; 197(11):4351-4359. PubMed ID: 27794001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
    Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
    J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.
    Neeland MR; Shi W; Collignon C; Taubenheim N; Meeusen EN; Didierlaurent AM; de Veer MJ
    J Immunol; 2016 Oct; 197(7):2704-14. PubMed ID: 27549170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.
    van den Berg RA; De Mot L; Leroux-Roels G; Bechtold V; Clement F; Coccia M; Jongert E; Evans TG; Gillard P; van der Most RG
    Front Immunol; 2018; 9():564. PubMed ID: 29632533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.
    Ko EJ; Lee YT; Kim KH; Lee Y; Jung YJ; Kim MC; Lee YN; Kang T; Kang SM
    J Immunol; 2017 Jan; 198(1):279-291. PubMed ID: 27881702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.